Vimarsana
Biggest News Aggregation in the World

Page 4 - Ptom Keith Roach News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ptom Keith Roach. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ptom Keith Roach Today - Breaking & Trending Today

One year anniversary of UK approving Oxford/AstraZeneca Covid vaccine - Vimarsana News

One year anniversary of UK approving Oxford/AstraZeneca Covid vaccine

Vaccination programme has been a phenomenal success, saving countless lives and reducing pressure on NHS 2.5 billion doses of the at-cost and UK-made

One year anniversary of UK approving Oxford/AstraZeneca COVID-19 vaccine - Vimarsana News

One year anniversary of UK approving Oxford/AstraZeneca COVID-19 vaccine

A year ago today, the UK became the first country in the world to approve the Oxford University/AstraZeneca vaccine.

Source: gov.uk
COVID: UK marks one-year anniversary of approving Oxford/AstraZeneca coronavirus vaccine - Vimarsana News

COVID: UK marks one-year anniversary of approving Oxford/AstraZeneca coronavirus vaccine

Boris Johnson has praised the Oxford/AstraZeneca vaccine for saving many millions of lives as the UK marks becoming the first country to approve the COVID vaccine exactly one year ago.

Outrage Over Dapagliflozin Withdrawal for Type 1 Diabetes in EU - Vimarsana News

Outrage Over Dapagliflozin Withdrawal for Type 1 Diabetes in EU

The voluntary withdrawal of the type 1 diabetes indication for dapagliflozin in the EU by AstraZeneca has been branded as 'appalling' and 'devastating', with questions raised as to why it was pulled.

AstraZeneca: NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) ISSUES POSITIVE RECOMMENDATION FOR TAGRISSO ? (osimertinib) IN ENGLAND FOR PATIENTS WITH EARLY-STAGE LUNG CANCER - Vimarsana News

AstraZeneca: NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) ISSUES POSITIVE RECOMMENDATION FOR TAGRISSO ? (osimertinib) IN ENGLAND FOR PATIENTS WITH EARLY-STAGE LUNG CANCER

Osimertinib will be made available via the Cancer Drugs Fund (CDF) to patients in England with completely resected early-stage IB-IIIA EGFR mutation-positive (EGFRm) non-small cell lung cancer (NSCLC).1